BioVersys Works to Bring Antibiotic Resistance to an End

Marcel Tigges; Marc Gitzinger

doi:10.2533/chimia.2014.888

BioVersys Works to Bring Antibiotic Resistance to an End

Authors

Marcel Tigges BioVersys AG, Hochbergerstrasse 60c, c/o Technologiepark, CH-4057 Basel, Switzerland. info@bioversys.com
Marc Gitzinger BioVersys AG, Hochbergerstrasse 60c, c/o Technologiepark, CH-4057 Basel, Switzerland

DOI:

https://doi.org/10.2533/chimia.2014.888

Keywords:

Antibiotic resistance, Bioversys, Life science start-up, Nosocomial infections, Tric, Tuberculosis

Abstract

BioVersys, founded in 2008, is working on bringing a technology for screening and for the development of 'transcriptional regulator inhibiting compounds' (TRICs) to patients in order to overcome antibiotic resistance. The co-founders share their view on what makes successful scientists pursue a career as start-up entrepreneurs rather than a classic academic career. They describe the history and milestones of their company, and how their everyday work differs from that of peers in an academic or industrial research setting.